AU Patent

AU2022271290A1 — Cdk2 degraders and uses thereof

Assigned to Kymera Therapeutics Inc · Expires 2023-11-23 · 2y expired

What this patent protects

The present invention provides compounds, compositions thereof, and methods of using the same.

USPTO Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: AU2022271290A1
Jurisdiction: AU
Classification: —
Expires: 2023-11-23
Drug substance claim: No
Drug product claim: No
Assignee: Kymera Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.